Managing Asthma Patients With AMAZE™: A Novel Disease Management Platform

AstraZeneca

Status: Completed

Conditions: Asthma

Treatments: Device: AMAZE™ Application; Device: AMAZE™ Dashboard

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT04868500

N4280000000

Details and patient eligibility

About

The primary study objective is to generate evidence as to the feasibility, usability, perceived value, and potential benefits of implementing the AMAZE™ platform into clinical practice.

Full description

AstraZeneca has developed the AMAZE™ disease management platform to be used across multiple disease indications to provide a unified experience for the management of participants throughout their participant care journey. AMAZE™ integrates multiple systems, including a patient mobile application where patients can enter daily symptoms and impact to communicate this information to their healthcare provider, as well as access disease educational materials. Implementation of AMAZE™ within clinical practice has not yet been evaluated. The results from this study will be used to inform any changes or modifications that need to be made to the technology platform, its implementation process, and explore impact on clinical outcomes.

Enrollment: 49 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• >18 years of age at the time of enrollment
• Clinically confirmed diagnosis of asthma
• Access to a smartphone with internet access with the following requirements: iOS (Operating System iOS 13 or newer and Devices iPhone 8 or newer) or Android (Operating System 8.0 or newer)
• Able to understand and speak English sufficiently to be able to use the AMAZE™ patient app
• Willingness to participate in a telephone interview and be audio-recorded
• Consenting to participate in the study

Exclusion criteria

• Current diagnosis of active chronic obstructive pulmonary disease (COPD) or any pulmonary diagnosis other than asthma
• Has a cognitive impairment, hearing difficulty, acute psychopathology, medical condition, or insufficient knowledge of the English language that, in the opinion of the investigator, would interfere with his or her ability to agree to participate and/or complete the ACT™.

Trial design

Primary purpose: Health Services Research

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

49 participants in 2 patient groups

Massachusetts General Hospital (MGH) Participants

Experimental group

Description:

Participants will use the AMAZE™ application to enter daily asthma symptoms and impact to communicate this information to their healthcare provider, as well as access disease educational materials up to six months.

Treatment:

Device: AMAZE™ Application

Massachusetts General Hospital (MGH) Clinical Site Staff

Experimental group

Description:

Clinical site staff will use the AMAZE™ dashboard for six months to identify usability and barriers, benefits, challenges, ease of implementation, and areas for improvement of the AMAZE™ dashboard in a clinical setting.

Treatment:

Device: AMAZE™ Dashboard